Immunex pilot development plant
Firm is building a $4 mil., 10,000 sq. ft. facility in Seattle to produce pharmaceuticals for clinical trials and expanded research. Immunex said the plant will allow it to refine production techniques which can be applied to a commercial scale manufacturing plant that Kodak and Immunex intend to construct in 1988. The pilot plant is owned by Immunex/Kodak joint venture Immunology Ventures.
You may also be interested in...
Just three years after Fresenius Kabi agreed a $4.75bn takeover of the US injectables specialist, Akorn has obtained approval from a US bankruptcy court for its sale to the company’s existing lenders, having filed for Chapter 11 bankruptcy earlier this year.
Dr Reddy’s has announced the launch of its OTC versions of Pataday olopatadine solution in the US. The firm’s entry into the OTC eyecare space follows other OTC launches of rivals to Voltaren and Nicorette earlier this year.
A number of anti-TIGIT drugs are jockeying for position to provide benefit as monotherapies and in combinations for non-small cell lung cancer and Merck's offering is looking to challenge Roche's tiragolumab for the lead.